Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and function

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 6, 2007, Pages 1190-1193

  Rose, Warren E ^a,b   Rybak, Michael J ^a,c   Tsuji, Brian T ^a,b,d   Kaatz, Glenn W ^a,c,e   Sakoulas, George ^f  

^a WAYNE STATE UNIVERSITY   (United States)

^b DETROIT RECEIVING HOSPITAL   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Pharmacodynamics; S. aureus; Vancomycin resistance

Indexed keywords

ACCESSORY GENE REGULATOR; DAPTOMYCIN; GENTAMICIN; PROTEIN; RIFAMPICIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIAL PROTEINS; CULTURE MEDIA; DAPTOMYCIN; MICROBIAL SENSITIVITY TESTS; POLYMORPHISM, GENETIC; STAPHYLOCOCCUS AUREUS; TRANS-ACTIVATORS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 34447581034     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm091     Document Type: Article

References (10)

1. Sakoulas G, Eliopoulos GM, Moellering RC Jr et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002; 46: 1492-502.
2. Tsuji BT, Rybak MJ, Cheung CM et al. Community- and health care-associated methicillin-resistant Staphylococcus aureus: A comparison of molecular epidemiology and antimicrobial activities of various agents. Diagn Microbiol Infect Dis 2007, in press.
3. Tsuji BT, Rybak MJ, Lau KL et al. Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51: 1089-91.
4. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing Sixteenth Edition: Approved Standard M100-S16. CLSI, Wayne, PA, USA, 2006.
5. Huang V, Rybak MJ. Evaluation of daptomycin activity against Staphylococcus aureus in an in vitro pharmacodynamic model under normal and simulated impaired renal function. J Antimicrob Chemother 2006; 57: 116-21.
6. Rybak MJ, Allen GP, Hershberger E. In vitro antibiotic pharmacodynamic models. In: Nightingale CH, Murakawa T, Ambrose PG. Antimicrobial Pharmacodynamics in Theory and Clinical Practice. Marcel Dekker, Inc., Now York, USA. 2002; 48-51.
7. Cruciani M, Gatti G, Lazzarini L et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996; 38: 865-9.
8. Charles PG, Ward PB, Johnson PD et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004; 38: 448-51.
9. Sakoulas G, Moise-Broder PA, Schentag J et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42: 2398-402.
10. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115: 674-80.